Abstract
Heme oxygenase (HO) family catalyzes the conversion of heme into free iron, carbon monoxide and biliverdin. It possesses two well-characterized isoforms: HO-1 and HO-2. Under brain physiological conditions, the expression of HO-2 is constitutive, abundant and ubiquitous, whereas HO-1 mRNA and protein are restricted to small populations of neurons and neuroglia. HO-1 is an inducible enzyme that has been shown to participate as an essential defensive mechanism for neurons exposed to oxidant challenges, being related to antioxidant defenses in certain neuropathological conditions. Considering that neurodegenerative diseases (Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Multiple Sclerosis (MS)) and neuropsychiatric disorders (depression, anxiety, Bipolar Disorder (BD) and schizophrenia) are associated with increased inflammatory markers, impaired redox homeostasis and oxidative stress, conditions that may be associated with alterations in HO-levels/activity, the purpose of this review is to present evidence on the possible role of HO-1 in these Central Nervous System (CNS) diseases. In addition, the possible therapeutic potential of targeting brain HO-1 is explored in this review.
Keywords: Central nervous system, heme oxygenase-1, neurodegenerative diseases, neuropsychiatric disorders, neuroinflammation, oxidative stress.
Current Pharmaceutical Design
Title:Involvement of Heme Oxygenase-1 in Neuropsychiatric and Neurodegenerative Diseases
Volume: 24 Issue: 20
Author(s): Vivian B. Neis, Priscila B. Rosa, Morgana Moretti and Ana Lucia S. Rodrigues*
Affiliation:
- Department of Biochemistry, Center of Biological Sciences, Federal University of Santa Catarina, 88040-900, Florianópolis-SC,Brazil
Keywords: Central nervous system, heme oxygenase-1, neurodegenerative diseases, neuropsychiatric disorders, neuroinflammation, oxidative stress.
Abstract: Heme oxygenase (HO) family catalyzes the conversion of heme into free iron, carbon monoxide and biliverdin. It possesses two well-characterized isoforms: HO-1 and HO-2. Under brain physiological conditions, the expression of HO-2 is constitutive, abundant and ubiquitous, whereas HO-1 mRNA and protein are restricted to small populations of neurons and neuroglia. HO-1 is an inducible enzyme that has been shown to participate as an essential defensive mechanism for neurons exposed to oxidant challenges, being related to antioxidant defenses in certain neuropathological conditions. Considering that neurodegenerative diseases (Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Multiple Sclerosis (MS)) and neuropsychiatric disorders (depression, anxiety, Bipolar Disorder (BD) and schizophrenia) are associated with increased inflammatory markers, impaired redox homeostasis and oxidative stress, conditions that may be associated with alterations in HO-levels/activity, the purpose of this review is to present evidence on the possible role of HO-1 in these Central Nervous System (CNS) diseases. In addition, the possible therapeutic potential of targeting brain HO-1 is explored in this review.
Export Options
About this article
Cite this article as:
Neis B. Vivian , Rosa B. Priscila , Moretti Morgana and Rodrigues Lucia S. Ana *, Involvement of Heme Oxygenase-1 in Neuropsychiatric and Neurodegenerative Diseases, Current Pharmaceutical Design 2018; 24 (20) . https://dx.doi.org/10.2174/1381612824666180717160623
DOI https://dx.doi.org/10.2174/1381612824666180717160623 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Subtype Specific and Universal Somatostatin Analogues: Clinical Potential and Pitfalls
Current Pharmaceutical Design Bio-Antioxidants – A Chemical Base of Their Antioxidant Activity and Beneficial Effect on Human Health
Current Medicinal Chemistry Duloxetine in the Treatment of Depression: An Overview
Central Nervous System Agents in Medicinal Chemistry Upregulation of Suppressor of Cytokine Signaling 3 in Microglia by Cinnamic Acid
Current Alzheimer Research Proteasome Modulator 9 and Depression in Type 2 Diabetes
Current Medicinal Chemistry Restless Leg Syndrome Associated with Atypical Antipsychotics: Current Status, Pathophysiology, and Clinical Implications
Current Drug Safety Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Current Neuropharmacology Meet Our Editorial Board Member:
Current Neuropharmacology Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Antimicrobial Evaluation of Erythrinan Alkaloids from Erythrina cristagalli L.
Medicinal Chemistry Evaluation of Cell Tolerability of a Series of Lipoamino Acids Using Biological Membranes and a Biomembrane Model.
Current Drug Delivery The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children: Update
Recent Patents on Inflammation & Allergy Drug Discovery The Critical Period for Neuroprotection by Estrogen Replacement Therapy and the Potential Underlying Mechanisms
Current Neuropharmacology Ethosomes as Novel Vesicular Carrier: An Overview of the Principle, Preparation and its Applications
Current Drug Delivery Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Current Medicinal Chemistry Partial Dopamine Agonists and the Treatment of Psychosis
Current Neuropharmacology Recent Advances in the Discovery of Selective AMPA Receptor Positive Allosteric Modulators
Current Medicinal Chemistry Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy